Residual symptoms and comorbidity in panic disorder

被引:10
作者
Corominas, A
Guerrero, T
Vallejo, J
机构
[1] Hosp Mollet, Dept Psychiat, Barcelona 08100, Spain
[2] Pharma Res, Dept Psychiat Psychopharmacol & Mental Hlth, Barcelona, Spain
[3] Hosp Bellvitge Princeps Espanya, Dept Psychiat, Barcelona, Spain
关键词
panic disorder; comorbidity; residual symptoms;
D O I
10.1016/S0924-9338(02)00693-4
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The aim of this study was to assess the outcome of the comorbid conditions of panic disorder after 1 year of treatment, emphasizing the detection of residual symptoms and their relationship to other clinical variables, Methods: Subjects (N = 64) were assessed by the Structured Clinical Interview for DSM-III-R and the Eysenck Personality Questionnaire. Comorbidity with other disorders, scores on Hamilton Anxiety Rating Scale and Hamilton Depression Rating Scale were assessed at baseline and after 12 months. Criteria for residual anxiety/somatic symptoms were defined. Results: Reduction in generalized anxiety disorder rates accounted for a significant decrease in comorbidity at 1-year follow-up, with regard to baseline assessment. When the more severe symptoms of the disorder had remitted, a third of the patients referred physical symptoms with some concern over a fluctuating state of anxiety. The said symptoms were neither a recurrence of panic disorder nor did they account for other anxiety or somatoform disorders, Lower scores on extraversion predict higher risk of residual symptoms. Discussion: The persistence of residual anxiety/somatic symptoms in a third of the patients who apparently achieved a good response to treatment of panic disorder might characterize a minor form of chronic persistence of this condition. Conclusions: The subgroup of patients with residual symptoms would not be detectable by follow-up studies, which focus on the assessment of relapse of panic disorder by means of strictly defined diagnostic criteria. (C) 2002 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:399 / 406
页数:8
相关论文
共 34 条
[1]  
[Anonymous], 1978, Research Diagnostic Criteria
[2]  
Apfeldorf WJ, 2000, DEPRESS ANXIETY, V12, P78, DOI 10.1002/1520-6394(2000)12:2<78::AID-DA3>3.3.CO
[3]  
2-X
[4]  
BALLENGER JC, 1991, CLIN MANAGEMENT ANXI
[5]   The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder [J].
Bouffard, R ;
Hechtman, L ;
Minde, K ;
Iaboni-Kassab, F .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08) :546-554
[6]  
BREIER A, 1986, ARCH GEN PSYCHIAT, V43, P1029
[7]  
CASSANO GB, 1997, BIOL PSYCHIAT, V42, pS132
[8]   DRUG-TREATMENT OF PANIC DISORDER - COMPARATIVE EFFICACY OF ALPRAZOLAM, IMIPRAMINE, AND PLACEBO [J].
COLEMAN, JH ;
KLERMAN, GL ;
AYUSO, JL ;
BECH, P ;
BENKERT, O ;
BRANDON, S ;
CASSANO, GB ;
SILVA, JACE ;
CURTIS, GC ;
DELAFUENTE, JR ;
GUIMON, J ;
HIPPIUS, H ;
LECRUBIER, Y ;
LEON, CA ;
LOPEZIBOR, JJ ;
KATSCHNIG, H ;
MASSANA, J ;
MELLERGAARD, M ;
OTTOSON, JO ;
RAFAELSEN, OJ ;
ROSENBERG, R ;
ROTH, M ;
SEPULVEDA, J ;
SOLYOM, L ;
VERSIANI, M ;
WILMOTTE, J .
BRITISH JOURNAL OF PSYCHIATRY, 1992, 160 :191-202
[9]  
COROMINAS A, 1996, PUBLICACIONS U BARCE
[10]  
COROMINAS A, 1996, EUROPEAN NEUROPSY S4, V6, pS4